Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States20 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | graft versus host disease, immune system disorder | Recruiting | Not stated | 2026-09-29 | NCT06649201 | |
| High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy; Chemotherapy-induced Peripheral Neuropathy | Not yet recruiting | Phase 4 | 2026-09-22 | NCT07834281 | |
| Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreatic adenocarcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT06412510 | |
| Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | Cysts, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Pancreatic Cyst, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-09-15 | NCT05720338 | |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myelodysplastic syndrome, myeloid leukemia, myeloproliferative neoplasm, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT03471260 | |
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-10 | NCT03104491 | |
| Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not applicable | 2026-08-18 | NCT05831358 | |
| SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, gliosarcoma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-08-07 | NCT02455557 | |
| Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Not yet recruiting | Not applicable | 2026-08-06 | NCT05725421 | |
| Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, malignant glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-08-06 | NCT05565118 | |
| Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases | Spine Metastases; Spine Stereotactic Radiosurgery (sSRS) | Recruiting | Phase 2 | 2026-08-06 | NCT04218617 | |
| Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer | Localized Muscle Invasive Bladder Urothelial Carcinoma; Muscle-Invasive Bladder Carcinoma | Recruiting | Phase 1 | 2026-07-20 | NCT05833867 | |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-06-25 | NCT06447376 | |
| Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Not applicable | 2026-06-08 | NCT04545177 | |
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-06-03 | NCT03092856 | |
| Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-05-05 | NCT05400109 | |
| Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Active, not recruiting | Phase 1 | 2025-07-20 | NCT01843413 | |
| Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2025-02-28 | NCT03452579 | |
| Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkin's lymphoma, lymphocytic-histiocytic predominance, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2024-11-06 | NCT03712202 | |
| Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2022-11-16 | NCT03064867 |